About: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $84.69 (-0.17%)
DNTH NASDAQ Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. share price
Atividade de preço de DNTH
Último preço
$ 84,690
Variação (24h)
-0,14 USD (0,17%)
Volume
26.27K
Volume (média 4 sem.)
-
Fechamento anterior
$ 84,83
Último negócio
20 Nov, 2:30 pm GMT+0
Atrasado
20 Nov, 2:30 pm GMT+0
DNTH price performance
Atrasado
20 Nov, 2:30 pm GMT+0
DNTH details
quote.marketSignals